Vaccine Pharmacovigilance Experts are instrumental in ensuring the ongoing safety and efficacy of vaccines once they are distributed to the public. Their primary responsibility is to monitor, evaluate, and report on adverse events that may occur after vaccination. This includes gathering data from healthcare providers, patients, and clinical studies, which is then analyzed to identify any patterns or risks. These experts play a crucial role in detecting potential side effects that may not have been identified in clinical trials, thus safeguarding public health and maintaining the trust in immunization programs. Through their continuous monitoring, they contribute significantly to updating vaccine safety guidelines and improving the overall vaccination process.
Vaccine pharmacovigilance experts collaborate with regulatory agencies, pharmaceutical companies, and healthcare professionals to ensure that vaccines meet all safety and efficacy standards. They provide recommendations for risk management, assist in labeling and patient education, and help develop strategies for minimizing risks associated with immunizations. They are also involved in post-marketing surveillance, ensuring that any emerging safety concerns are promptly addressed. Their work ensures that vaccines remain safe and effective, benefiting populations worldwide. As vaccine deployment continues to expand globally, their expertise is vital in adapting to new challenges and ensuring the effectiveness of immunization efforts. Their role is key in maintaining public confidence, as they help ensure that vaccines are both safe and reliable for all age groups. By continuously evaluating and improving vaccine safety, they are integral to the fight against infectious diseases worldwide.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States